Publications by authors named "G P HERMAN"
Article Synopsis
- The study investigates how antiviral monoclonal antibodies (mAbs), particularly casirivimab and imdevimab (CAS+IMD), affect immune responses when individuals are vaccinated against SARS-CoV-2 after receiving mAb treatment.
- It was found that the presence of CAS+IMD during vaccination reduced the effectiveness of the vaccine in generating neutralizing antibodies, though other immune responses remained intact.
- This reduction in antibody production is linked to "epitope masking," but can be reversed with booster shots, and influences the immune response differently in those who had not yet begun their natural immunity when treated with mAbs.
Article Synopsis
- Fibrodysplasia ossificans progressiva (FOP) is a rare condition where bones form in soft tissue, referred to as heterotopic ossification (HO), and this study examined imaging methods to identify and measure new HO lesions.
- The research analyzed data from a phase 2 clinical trial comparing the effectiveness of garetosmab (a therapy) with a placebo in adults with FOP, utilizing both PET/CT and CT scans to detect lesions over 28 weeks.
- Results showed that both PET/CT and CT-only methods detected a similar number and volume of new lesions, indicating that CT-only imaging is an effective alternative for monitoring HO changes in FOP patients.
Article Synopsis
- Pregnant women with COVID-19 are at higher risk for severe outcomes, and this study evaluated the safety and effectiveness of the monoclonal antibody treatment CAS+IMD in this population.* -
- The study, which involved 82 pregnant participants, found that CAS+IMD was well tolerated with minimal adverse reactions, and it effectively reduced viral loads without significantly affecting fetal development.* -
- Overall, the treatment showed promising safety and efficacy, suggesting it could be a viable option for managing COVID-19 in pregnant women, although conclusions about its effects are limited due to a small number of placebo recipients.*
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.
J Pediatric Infect Dis Soc
November 2024
Article Synopsis
- A clinical trial assessed the safety of the combination of casirivimab and imdevimab (CAS + IMD) in children with COVID-19.
- The results showed that the treatment was well tolerated, similar to findings in adults, with minimal immune response side effects.
- The study supports further development of advanced monoclonal antibodies for children at higher risk for COVID-19.
Background: In 2021, the EAU Guidelines implemented a novel, expert opinion-based follow-up scheme, with a three-risk-category system for clear cell (cc) and non-cc renal cell carcinoma (non-ccRCC) after surgery with curative intent. We aimed to validate the novel follow-up scheme and provide data-driven recurrence estimates according to risk groups, to confirm or implement the oncologic surveillance strategy.
Methods: We identified 5,320 patients from a prospectively maintained database involving 28 French referral centers.